1040682-68-5 Usage
Uses
Used in Pharmaceutical Synthesis:
1H-Pyrrolo[3,2-c]pyridine-4-carbonitrile is used as a key intermediate in the synthesis of various active pharmaceutical ingredients. Its unique structure and reactivity make it a valuable component in the development of new drugs.
Used in Organic Chemistry:
In the field of organic chemistry, 1H-Pyrrolo[3,2-c]pyridine-4-carbonitrile is used as a building block for the creation of more complex molecules. Its presence in the synthesis process can lead to the formation of a wide range of organic compounds with diverse applications.
Used in Research and Development:
1H-Pyrrolo[3,2-c]pyridine-4-carbonitrile is also employed in research and development settings, where its properties and reactions are studied to understand its potential applications and to develop new methodologies for its synthesis and use. This can lead to advancements in both pharmaceutical and organic chemistry fields.
Check Digit Verification of cas no
The CAS Registry Mumber 1040682-68-5 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,4,0,6,8 and 2 respectively; the second part has 2 digits, 6 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 1040682-68:
(9*1)+(8*0)+(7*4)+(6*0)+(5*6)+(4*8)+(3*2)+(2*6)+(1*8)=125
125 % 10 = 5
So 1040682-68-5 is a valid CAS Registry Number.
1040682-68-5Relevant academic research and scientific papers
THERAPEUTIC INHIBITORY COMPOUNDS
-
Paragraph 00682, (2018/03/26)
Provided herein are heterocyclic derivative compounds and pharmaceutical compositions comprising said compounds that are useful for inhibiting plasma kallikrein. Furthermore, the subject compounds and compositions are useful for the treatment of diseases wherein the inhibition of plasma kallikrein inhibition has been implicated, such as angioedema and the like.
2, 4-DIAMINE-PYRIMIDINE DERIVATIVE AS SERINE/THREONINE KINASE INHIBITORS
-
Page/Page column 38; 39, (2013/07/05)
Compounds having the formula I wherein A, Rla, Rlb, R2, R3, R4, R5, R6, R7, Rs, Ra, Rb, X1, X2, X3 and n are as defined herein are inhibitors of PAK1. Also disclosed are compositions and methods for treating cancer and hyperproliferative disorders
